Notice of Results

RNS Number : 7057V

Evgen Pharma PLC

04 December 2019

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Notice of results

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it will issue its unaudited interim results for the six months ended 30 September 2019 on Tuesday, 17 December 2019.

Enquiries:

Evgen Pharma plc www.evgen.com		via Walbrook
Dr Stephen Franklin, CEO
Richard Moulson, CFO
finnCap www.finncap.com		[phone]
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane, Manasa Patil (ECM)
WG Partners LLP		[phone]
Nigel Barnes / Claes Spång
Walbrook PR	[phone] or [e-mail]
Paul McManus / Anna Dunphy		[phone] / [phone]

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  

For further information, please visit: www.evgen.com 

 

END

 

 

NORFSWFILFUSESE